Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime LUMRYZ versus a twice-nightly immediate-release oxybate treatment option.

Turning back the clock on aging immune systems: New treatment rejuvenates elderly defenses

Study demonstrated that selectively reducing myeloid-biased hematopoietic stem cells (my-HSCs) in aged mice rejuvenated the immune system, enhanced lymphopoiesis, reduced inflammation, and improved responses to

April 1, 2024

Time-lapsed images show how magnesium ions coordinate double-stranded breaks in CRISPR-Cas9

The gene-editing technology known as CRISPR has led to revolutionary changes in agriculture, health research and more.

November 3, 2023

Out-of-state officers shot and killed a man wielding two knives blocks away from the RNC, police say – The Cannabist

By JAKE OFFENHARTZ MILWAUKEE (AP) — Ohio police officers in Wisconsin for the Republican National Convention shot and killed a man who was wielding two

July 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.